BioSpace News Archive

Vaccinex, Inc. previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in compliance with Nasdaq’s minimum bid price requirement and that Nasdaq could move to suspend trading of the common stock and to delist the Company’s securities unless the company appealed Nasdaq’s determination.

Panbela Therapeutics, Inc today announces the publication of preclinical data from studies of ivospemin (also known as SBP-101) and eflornithine (also known as CPP-1X or DFMO) research in multiple myeloma (cell lines).

Technoderma Medicines, Inc. is pleased to report that the Company has completed a Phase 1 clinical trial (NCT05525468) of TDM-180935 topical ointment for Atopic Dermatitis (AD).

On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany.

Anitoa Systems, LLC, a Silicon Valley biotechnology company and market leader in rapid, portable molecular testing, announced worldwide availability of its all-in-one swine flu test solution for live stocks.

Inhibikase Therapeutics, Inc. today announced the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro and to review the data establishing doses of IkT-001Pro bioequivalent to 400 mg and 600 mg imatinib mesylate.

Arcturus Therapeutics Holdings Inc. today announced that Joseph Payne, President & Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, on Tuesday, January 9, 2024, at 3:00 p.m. Pacific Time.

Viracta Therapeutics, Inc. today announced that additional data from the Phase 1b/2 clinical trial of Nana-val (nanatinostat in combination with valganciclovir) in patients with recurrent or metastatic (R/M) Epstein-Barr virus-positive (EBV+) nasopharyngeal carcinoma (NPC) showed two ongoing confirmed partial responses (PRs) at higher dose levels.

AptarGroup, Inc., a global leader in drug and consumer product dosing, dispensing and protection technologies, is announcing a contract with the U.S. Food and Drug Administration to study the challenges with developing low Global Warming Potential propellant metered dose inhalers.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) a clinical and diagnostic laboratory developing a liquid biopsy molecular diagnostic tests with a focus on hard to detect and treat cancers, is pleased to announce today that the Canadian Intellectual Property Office (CIPO) has granted patent N° 2.906.236, on October 31, 2023.